We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently published a list of Jim Cramer Discusses These 13 Stocks & Rejects The AI PC Super Cycle. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against ...

after pleading guilty to one count of being a Serious Violent Felon in Possession of a Firearm and one count of Dealing in a Narcotic Drug, both Level 4 felonies. Johnson’s sentence includes ...

Johnson & Johnson's Q4 2024 earnings missed ... JNJ's long-term growth strategy focuses on high-growth markets and promising pipeline products. JNJ's MedTech division showed strong performance ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

House Speaker Mike Johnson says former President Joe Biden’s last-minute pardons of his family members were "shocking" and "disgusting." "It was shocking. I mean, it was shocking what President ...

Johnson & Johnson (JNJ ... as generics launch for its blockbuster anti-inflammatory arthritis drug Stelara. The drug is also now facing pricing pressures from a newly negotiated price with ...

Overall, Johnson & Johnson ... property against generic competition. This quarter, sales in its Innovative Medicine segment grew by 4.4% year over year, led by products like Darzalex in oncology ...